IceCure secures China patent for novel cryogen flow control
Cryogenic flow control enhances the efficacy and precision of cryoablation procedures Robust IP portfolio becomes increasingly strategic as global interest in IceCure’s platform and next-generation cryoablation technologies grows following ProSense®’s recent FDA marketing authorization in low-risk breast cancer CAESAREA, Israel, Dec. 5, 2025 /PRNewswire/ — IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the…